AGIOS PHARMACEUTICALS, INC. Cash Provided by (Used in) Operating Activities, Discontinued Operations
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Cash Provided by (Used in) Operating Activities, Discontinued Operations of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-15.
Discontinued › Cash Flow › Operating Activities
us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations · last filed 2024-02-15
- AGIOS PHARMACEUTICALS, INC. cash provided by (used in) operating activities, discontinued operations for the quarter ending 2022-12-31 was $0.00.
- AGIOS PHARMACEUTICALS, INC. cash provided by (used in) operating activities, discontinued operations for the quarter ending 2022-09-30 was $0.00.
- AGIOS PHARMACEUTICALS, INC. cash provided by (used in) operating activities, discontinued operations for the quarter ending 2022-06-30 was $0.00.
- AGIOS PHARMACEUTICALS, INC. cash provided by (used in) operating activities, discontinued operations for the quarter ending 2022-03-31 was $0.00.
- AGIOS PHARMACEUTICALS, INC. cash provided by (used in) operating activities, discontinued operations for fiscal 2023 was $0.00.
- AGIOS PHARMACEUTICALS, INC. cash provided by (used in) operating activities, discontinued operations for fiscal 2022 was $0.00.
- AGIOS PHARMACEUTICALS, INC. cash provided by (used in) operating activities, discontinued operations for fiscal 2021 was -$93.23M.
- AGIOS PHARMACEUTICALS, INC. cash provided by (used in) operating activities, discontinued operations for fiscal 2020 was -$46.81M.
| Period end | Cash Provided by (Used in) Operating Activities, Discontinued Operations 3 month | Cash Provided by (Used in) Operating Activities, Discontinued Operations 6 month | Cash Provided by (Used in) Operating Activities, Discontinued Operations 9 month | Cash Provided by (Used in) Operating Activities, Discontinued Operations 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-15 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $0.00 derived: sum of 2 quarters · filed 2024-02-15 | $0.00 derived: sum of 3 quarters · filed 2024-02-15 | $0.00 10-K · filed 2024-02-15 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | -$4.10M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | -$4.10M derived: sum of 3 quarters · filed 2024-02-15 | -$14.42M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-05 | -$4.10M derived: sum of 2 quarters · filed 2024-02-15 | -$14.42M derived: sum of 3 quarters · filed 2024-02-15 | -$62.71M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | -$4.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$14.42M derived: sum of 2 quarters · filed 2024-02-15 | -$62.71M derived: sum of 3 quarters · filed 2024-02-15 | -$93.23M 10-K · filed 2024-02-15 |
| 2021-09-30 | -$10.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$58.61M derived: sum of 2 quarters · filed 2022-11-03 | -$89.13M 10-Q · filed 2022-11-03 | -$87.39M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | -$48.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$78.81M 10-Q · filed 2022-08-04 | -$77.07M derived: sum of 3 quarters · filed 2023-02-23 | -$88.67M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | -$30.52M 10-Q · filed 2022-05-05 | -$28.78M derived: sum of 2 quarters · filed 2023-02-23 | -$40.37M derived: sum of 3 quarters · filed 2023-02-23 | -$50.76M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | -$9.85M derived: sum of 2 quarters · filed 2023-02-23 | -$20.24M derived: sum of 3 quarters · filed 2023-02-23 | -$46.81M 10-K · filed 2023-02-23 |
| 2020-09-30 | -$11.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$21.98M derived: sum of 2 quarters · filed 2021-11-03 | -$48.56M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | -$10.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | -$36.96M 10-Q · filed 2021-07-29 | ||
| 2020-03-31 | -$26.58M 10-Q · filed 2021-04-29 | |||
| 2019-12-31 | -$134.47M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |